Streetbeat News

IMNM

Immunome, Inc.

Industry

Biotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Open

10.24

Mkt cap

806M

Volume

674K

High

10.47

P/E Ratio

-1.20

52-wk high

30.96

Low

9.51

Div yield

N/A

52-wk low

8.97

Immunome, Inc. has successfully closed an upsized public offering, raising significant capital through the sale of 22,258,064 shares, including additional shares purchased by underwriters. The offering was priced at $7.75 per share.

Portfolio Pulse from

January 31, 2025 | 9:15 pm

Immunome is poised to challenge its competitors with its new product, Varegacestat. This development could enhance its market position and attract investor interest.

Portfolio Pulse from

January 30, 2025 | 3:45 pm

Immunome, Inc. has announced the pricing of an upsized public offering of 19,354,839 shares of its common stock at $7.75 per share, aiming to raise significant capital for its cancer therapy developments.

Portfolio Pulse from

January 30, 2025 | 4:30 am

Immunome, Inc. announced inducement grants of stock options to new employees under Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

January 02, 2025 | 11:30 pm

Immunome, Inc. announced inducement grants of non-statutory stock options to 15 new employees under its 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

December 02, 2024 | 11:45 pm

Immunome, Inc. (IMNM) reported a Q3 loss of $0.78 per share, missing the Zacks Consensus Estimate of a $0.60 loss. This is a larger loss compared to $0.36 per share a year ago.

Portfolio Pulse from

November 13, 2024 | 11:30 pm

Immunome, Inc. (NASDAQ:IMNM) presented promising preclinical data for its cancer therapy IM-1021 and proprietary ADC payload HC74, showing superior potency and efficacy in preclinical models. An IND submission is expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:11 pm

Wedbush analyst David Nierengarten has reiterated an Outperform rating for Immunome (NASDAQ:IMNM) and maintained a price target of $33.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 3:06 pm

Immunome, Inc. (NASDAQ:IMNM) will present a poster on the preclinical evaluation of its ROR1-targeted antibody drug conjugate, IM-1021, at the 36th EORTC-NCI-AACR Symposium in Barcelona on October 24, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:02 pm

In Friday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, Allakos, and Unicycive Therapeutics, while Akanda, Dogwood Therapeutics, and Nexalin Technology were among the losers.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.